Company: ELV
Filing Date: 2025-07-17
Form Type: 10-Q
Source: 0001156039-25-000114
Chunk: 100

Company: Elevance Health, Inc.
Filing Date: 2025-07-17
Form: 10-Q
Item: Item 2
Chunk 100
---
 Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2024 Annual Report on Form 10-K.

For additional information regarding our sources and uses of capital during the three and six months ended June 30, 2025, see Note 5, “Investments,” Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

-51-

Liquidity

A summary of our major sources and uses of cash and cash equivalents for the six months ended June 30, 2025 and 2024 is as follows:

 Six Months Ended  June 30 20252024ChangeSources of Cash:Net cash provided by operating activities$3,071 $2,425 $646 Proceeds from the sale of subsidiaries, net of cash sold— 399 (399)Issuances of short- and long-term debt, net of repayments— 2,580 (2,580)Proceeds from sales, maturities, calls and redemptions of investments, net of purchases329 — 329 Changes in securities lending payable466 320 146 Proceeds from issuance of common stock under employee stock plans21 157 (136)Changes in bank overdrafts631 — 631 Total sources of cash4,518 5,881 (1,363)Uses of Cash:Purchases of investments, net of proceeds from sales, maturities, calls and redemptions— (1,415)1,415 Purchases of subsidiaries, net of cash acquired— (1,124)1,124 Repurchase and retirement of common stock(1,258)(1,029)(229)Purchases of property and equipment(463)(602)139 Repayments of short- and long-term debt, net of issuances(1,255)— (1,255)Cash dividends(771)(757)(14)Changes in securities lending collateral(466)(321)(145)Changes in bank overdrafts— (479)479 Other uses of cash, net(35)(157)122 Total uses of cash(4,248)(5,884)1,636 Effect of foreign